Dot size, lead time, fallibility, and impact on survival: Continuing controversies in mammography

American Journal of Roentgenology

Volumn 176, Issue 5, 2001, Pages 1123-1130

  Berlin, L ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; LAW SUIT; MAMMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME;

EID: 0035048694     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.176.5.1761123     Document Type: Review

References (59)

1. The missed breast cancer: Perceptions and realities
2. Getting to the core of mistakes in medicine
3. Reporting of errors may trigger minefield
4. Putting the risk of breast cancer in perspective
5. Advertisement
6. Breast cancer: Promising new technology improves diagnosis. Chicago Life (special advertising supplement)
7. Know your options for breast cancer. (JAMA patient page)
8. From cause to cure: Breast cancer (special advertising supplement)
9. Advertisement
10. Can false positives be reduced without endangering patients?
11. Breast imaging reporting and data system: Interand intraobserver variability in feature analysis and final assessment
12. Double reading
13. Potential contribution of computer-aided detection to the sensitivity of screening mammography
14. Standardized abnormal interpretation and cancer detection ratios to assess reading volume and reader performance in a breast screening program
15. After 40 years, mammography remains as much emotion as science
16. Breast imaging: From 1965 to the present
17. Age-related accuracy of screening mammography: How should it be measured?
18. Determining the efficacy of breast cancer screening
19. Breast cancer screening among women young than age 50: A current assessment of the issues
20. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy
21. Screening mammography and public health policy: The need for perspective
22. Recent trends in U. S. breast cancer incidence, survival and mortality rates
23. Mammographic screening for women aged 40 to 49 years: The primary, care practitioner's dilemma
24. The breast-screening brawl
25. Other voices weigh in on mammography decision
26. Hälsokontroller med mammografi minskar inte dödlighet i bröstcancer
27. No need to reconsider breast screening programme on basis of results from defective study
28. 16-Year mortality from breast cancer in the UK trial of early detection of breast cancer
29. Breast cancer: Computer simulation method for estimating optimal intervals for screening
30. Living proof: Mammograms are not always enough
31. Is screening for breast cancer with mammography justifiable?
32. Assessment of nationwide cancer-screening programmes
33. Study criticizes use of mammograms as screening tool and draws fire itself
34. "Benign" tumors and "early detection" in mammography-screened patients of a natural cohort with breast cancer
35. Breast screening in women aged 40-49 years: What next?
36. The influence of margin width on local control of ductal carcinoma in situ of the breast
37. Ductal carcinoma in situ
38. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years
39. Trends in breast cancer incidence, survival, and mortality
40. The Swedish Two-County Trial twenty years later
41. Are increasing 5-year survival rates evidence of success against cancer?
42. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: Comparison of observed with predicted mortality
43. Canadian National Breast Screening Study-2: 13-Year results of a randomized trial in women aged 50-59 years
44. Activist says study shows need for self-exams
45. We survive together
46. Stage at diagnosis and treatment patterns among older women with breast cancer: An HMO and fee-for-service comparison
47. Women's understanding of the mammography screening debate
48. Routine screening for lung cancer?
49. Stare-of-the-art breast imaging: Can we afford it?
50. Best ways to screen, treat breast cancer still elusive
51. Screening for breast and cervical cancer as a common cause for litigation